【摘要】 目的观察芬太尼透皮贴剂治疗中度癌痛病人的效果,为恰当选择使用芬太尼透皮贴剂的时机提供临床依据。方法2003年3月~12月在哈尔滨医科大学附属肿瘤医院宁养院接受宁养服务的中度癌痛患者108例,单中心开放试验给药,自身对照方法进行研究,观察周期28天。结果符合入组标准患者108例,其中完成15天连续用药患者98例,治疗前疼痛评分平均为5.2173±0.3185,第15天为0.9184±0.7822,其中79.6%的患者达到基本无痛,其他患者仅有轻度疼痛,从平均用药剂量及疼痛评分变化曲线图可以发现,疼痛强度很快下降,而平均药物剂量增长缓慢,尽早给癌痛患者进行规范化的疼痛处理,相对较低的剂量即可取得良好镇痛效果。结论芬太尼透皮贴剂可以安全用于中度癌痛的治疗。我们认为最佳使用时机为常规一、二阶梯镇痛药物效果不满意,疼痛评分在4~6分以上即可使用,尽早减轻疼痛,提高患者的生活质量。更多还原

【Abstract】 Objective: To observe the effects of Duragesic on the home treatment of moderately advanced cancer pain(MACP) and offer some data for the clinical application. Methods: From March to December of 2003,108 patients with MACP were administered by single central opening test and studied by own control for 28 days. Results: The overall were consistent with the standard of the treatment group; 98 patients of the total had been administered for 15 days running. Before treatment,mean cancer pain score was 5.2173±0.3185, 0.9184±0.7822 at Day 15; 79.6% of the patients hardly felt pains,and others,a bit of pains. Conclusion: Duragesic can be safely used to treat MACP. We suggest that the best time to administer should be: when the pain-killer of the first or second step doesn’t effect any more, and, cancer pain score is over 4～6. Thus, administering the patients low doses of Duragesic as early as possible can not only ease the patients’ pains but also improve the quality of their life.更多还原